Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
TruBridge, Inc. and investors L6 Holdings Inc. and Pinetree Capital Ltd. entered a cooperation agreement that reshapes the company’s board and formalizes how these investors will act. L6 Holdings reports beneficial ownership of 2,130,000 TruBridge common shares, or 14.2% of the class, while Pinetree reports 850,000 shares, or 5.7%.
The board will be expanded from nine to ten directors and Damien Leonard will be appointed as a new director and nominated for election at the 2026 annual meeting, with an expected role on the Compensation Committee. Several long-tenured directors are expected to retire after the 2026 and 2027 annual meetings, and the board size is to be kept at no more than seven directors from the 2026 meeting through the cooperation agreement’s termination. In return, the reporting persons agree to voting commitments aligned with board recommendations in most cases, customary standstill and non‑disparagement provisions, and a cap on acquiring more than 20% of TruBridge’s outstanding common stock.
TruBridge, Inc. entered into a cooperation agreement with Pinetree Capital Ltd. and L6 Holdings Inc., under which the company will expand its board by one seat and appoint Damien Leonard as a director, effective January 12, 2026, and nominate him at the 2026 annual meeting. The company confirmed that director David A. Dye will not stand for reelection at that meeting, and two additional long‑serving directors will retire at the 2026 annual meeting, with another long‑serving director retiring at the 2027 annual meeting. After the 2026 annual meeting, the board will be capped at seven directors without Pinetree’s consent, and the board will give due and serious consideration to a Pinetree‑recommended candidate in connection with the 2027 transition.
During the term of the agreement, Pinetree will generally vote its TruBridge shares in line with the board’s recommendations, subject to specified exceptions, and is subject to standstill and non‑disparagement provisions, including a cap on beneficial ownership at 20% of outstanding common stock. Mr. Leonard is expected to join the compensation committee, has waived his director fees, and there are no disclosable related‑party transactions or family relationships tied to his appointment.
TruBridge, Inc. (TBRG) reporting persons filed an amended Form 4 to update recent open-market purchases of common stock. Pinetree Investment Partnership bought 20,707 shares at a weighted average price of $20.42 on 11/17/2025, 3,639 shares at $20.84 on 11/18/2025, and 8,501 shares at $20.70 on 11/19/2025, all reported as indirect ownership. The amendment adds that L6 Holdings Inc. acquired 5,000 shares on 11/19/2025 at a weighted average price of $20.52. Following these transactions, one indirect position is shown at 850,000 shares and another at 2,000,000 shares.
TruBridge, Inc. (TBRG) reported insider share purchases by group filers including L6 Holdings Inc. and Pinetree Capital Ltd. Acting through Pinetree Investment Partnership, they bought 20,707 common shares on 11/17/2025 at a weighted average price of $20.42, 3,639 shares on 11/18/2025 at $20.84, and 8,501 shares on 11/19/2025 at $20.70.
After these purchases, one indirect holding line shows 850,000 TruBridge common shares attributed to Pinetree Investment Partnership, while another line shows 1,995,000 shares held indirectly by L6 Holdings Inc. The reporting persons state that prices are weighted averages over multiple trades within the disclosed ranges and that they may be deemed part of a group owning over 10% of TruBridge’s outstanding securities.
TruBridge, Inc. (TBRG) reported insider buying by its Chief Business Officer, who filed a Form 4 as a single reporting person. The officer purchased common stock in multiple open-market transactions on November 11, 12, 13, 14 and 17, 2025.
The reported weighted average purchase prices were $19.39, $19.95, $20.16, $20.15 and $20.46 per share, each based on multiple trades within stated intraday price ranges. Following these transactions, the officer directly beneficially owned 57,492 shares of TruBridge common stock.
TruBridge, Inc. reported Q3 2025 results, showing steady revenue and a swing to profitability. Total revenue was $86,106 thousand versus $84,700 thousand a year ago, with segment revenue of $54,501 thousand from Financial Health and $31,605 thousand from Patient Care. Operating income rose to $4,068 thousand from $2,814 thousand. Net income was $5,602 thousand compared with a net loss of $9,148 thousand in Q3 2024, or $0.37 per diluted share.
For the nine months, revenue reached $259,043 thousand versus $254,416 thousand, and net income was $8,641 thousand versus a net loss of $15,390 thousand. Interest expense declined year over year, and the company recorded an income tax benefit influenced by the July 2025 OBBBA legislation allowing deductibility of domestic R&D. Cash from operations was $28,107 thousand year-to-date, ending cash was $19,920 thousand, and total debt obligations were $165,166 thousand, with long‑term debt of $161,363 thousand. Deferred revenue ended at $8,197 thousand. As of November 4, 2025, shares outstanding were 15,008,986.
TruBridge, Inc. filed a current report to let investors know it has released financial information for the third quarter ended September 30, 2025. The company states that on November 6, 2025 it issued a press release covering its results of operations and financial condition for this period.
The press release is included as Exhibit 99.1 and is described as being furnished to, but not filed with, the Securities and Exchange Commission. TruBridge’s common stock, with a par value of $0.001 per share, trades on The NASDAQ Stock Market LLC under the symbol TBRG.
TruBridge, Inc. (TBRG) reported an insider equity award on Form 4. On 10/15/2025, the company’s Chief Business Officer received a grant of 7,492 shares of restricted common stock at a stated price of $0.
The award vests in three equal annual installments, with the first tranche vesting on the first anniversary of the grant date. Following this transaction, the reporting person beneficially owned 7,492 shares, held directly. The filing notes the transaction is exempt under Rule 16b-3(d).
Nellore-affiliated holders disclosed a combined 5.2% ownership of TrueBridge, Inc. common stock, representing 789,472 shares of 15,011,642 outstanding shares as of 08/05/2025. The filing breaks ownership across entities: Nellore Capital Management LLC and individual managing member Sakya Duvvuru report shared voting and dispositive power over 789,472 shares; Nellore Capital Partners LP and related GP entities report direct ownership of 574,123 shares (3.8%). All reporting persons state they do not hold the shares to change or influence control and filed under the passive reporting Schedule 13G conditions. The issuer's principal office is listed in Mobile, Alabama.
TruBridge, Inc. (TBRG) reports an initial Form 3 for Michael Daughton, identified as Chief Business Officer and director. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/06/2025. This is an initial disclosure required when an officer/director becomes subject to Section 16 reporting; it records the absence of owned equity or derivative positions rather than a transfer or sale.